John Capek - Abbott Laboratories Insider

ABTT34 -- Brazil Stock  

BRL 58.46  0.96  1.62%

Executive VP of Ventures

Dr. John M. Capek, Ph.D. is Executive Vice President Ventures of the Company. Previously, he served as Senior Vice President, Abbott Vascular, heading up Abbott global vascular business. Dr. Capek served in various management roles at Guidant, including president, Guidant Vascular Intervention and Vice President and General Manager of Bioabsorbable Vascular Solutions. He also served as Vice President and General Manager of Guidant Germany and Vice President, Marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly Company
Age: 54  EVP Since 2015      
224-667-6100  http://www.abbott.com
Capek has a Bachelor degree in Biomedical Engineering, a Master degree in Biomedical Engineering, a Master degree in Electrical Engineering, a Ph.D. in Biomedical Engineering and a Master degree in Business Administration from Rensselaer Polytechnic Institute.

John Capek Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 2.85 % which means that it generated profit of $2.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 1.36 % meaning that it generated $1.36 on every $100 dollars invested by stockholders.
The company has accumulated 27.92 B in total debt with debt to equity ratio (D/E) of 89.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbott Laboratories has Current Ratio of 2.21 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 1 records

EVP Since

Marc ReedVerizon Communications
2012

Entity Summary

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company was founded in 1888 and is headquartered in Abbott Park, Illinois. Abbott Laboratories operates under Medical Devices classification in Brazil and traded on Sao Paolo Stock Exchange. It employs 99000 people.Abbott Laboratories (ABTT34) is traded on Sao Paolo Stock Exchange in Brazil. It is located in 100 Abbott Park Road and employs 99,000 people.

Abbott Laboratories Leadership Team

Scott White, President
Samuel Scott, Director
Deepak Nath, President
Jaime Contreras, President
Roger Bird, President
Nancy McKinstry, Director
Heather Mason, President
James Farrell, Director
Phebe Novakovic, Director
JeanYves Pavee, President
Andrew Lane, President
Roxanne Austin, Director
Georges Vos, President
Stephen Fussell, President
Thomas Freyman, EVP
Sally Blount, Director
Daniel Starks, Director
Thomas Frinzi, President
Eric Fain, President
John Capek, EVP
Robert Alpern, Director, Ph.D
Murthy Simhambhatla, President
Miles White, Chairman
Robert Ford, President
Glenn Tilton, Director
Richard Ashley, EVP
Michael Rousseau, President
Edward Liddy, Director
Hubert Allen, EVP
Charles Foltz, President
Brian Yoor, CFO
John Stratton, Director
Joseph Manning, President
Jared Watkin, President
William Osborn, Director
Brian Blaser, EVP
Michael Warmuth, President
Robert Funck, President
Daniel Salvadori, President

Stock Performance Indicators

Current Sentiment - ABTT34

Abbott Laboratories Investor Sentiment
Most of Macroaxis users are presently bullish on Abbott Laboratories. What is your sentiment towards investing in Abbott Laboratories? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Abbott Laboratories and Microsoft. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.